Mallinckrodt (NYSE:MNK) had its target price reduced by SVB Leerink from $2.00 to $1.50 in a report issued on Monday, Benzinga reports. They currently have a market perform rating on the stock. SVB Leerink also issued estimates for Mallinckrodt’s Q4 2020 earnings at $1.44 EPS, FY2020 earnings at $6.32 EPS, FY2021 earnings at $2.87 EPS, FY2022 earnings at $1.62 EPS and FY2023 earnings at $1.51 EPS.
Several other research firms have also recently weighed in on MNK. Barclays reiterated a hold rating on shares of Mallinckrodt in a research report on Wednesday, August 5th. Piper Sandler lowered shares of Mallinckrodt from a neutral rating to an underweight rating in a research note on Tuesday, August 4th. ValuEngine raised shares of Mallinckrodt from a sell rating to a hold rating in a research note on Tuesday, September 1st. JPMorgan Chase & Co. lowered shares of Mallinckrodt from a neutral rating to an underweight rating in a research note on Tuesday, May 19th. Finally, BMO Capital Markets reduced their price objective on shares of Mallinckrodt from $4.00 to $2.00 and set a market perform rating for the company in a research note on Wednesday, August 5th. Four investment analysts have rated the stock with a sell rating and seven have given a hold rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $2.70.
Mallinckrodt stock opened at $1.13 on Monday. The company has a debt-to-equity ratio of 5.39, a quick ratio of 1.23 and a current ratio of 1.48. The firm has a market cap of $95.59 million, a price-to-earnings ratio of -0.04, a price-to-earnings-growth ratio of 0.01 and a beta of 3.00. Mallinckrodt has a 1 year low of $1.00 and a 1 year high of $6.42. The firm’s 50 day moving average price is $1.59 and its two-hundred day moving average price is $2.52.
Mallinckrodt (NYSE:MNK) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $1.89 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.34 by $0.55. The firm had revenue of $700.90 million for the quarter, compared to analyst estimates of $630.19 million. Mallinckrodt had a negative net margin of 89.94% and a positive return on equity of 34.26%. The firm’s quarterly revenue was down 14.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.53 earnings per share. As a group, equities analysts predict that Mallinckrodt will post 6.33 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Aperio Group LLC increased its stake in Mallinckrodt by 23.1% in the first quarter. Aperio Group LLC now owns 33,760 shares of the company’s stock valued at $66,000 after acquiring an additional 6,338 shares during the period. Virtu Financial LLC bought a new stake in Mallinckrodt in the second quarter valued at about $28,000. California Public Employees Retirement System increased its stake in Mallinckrodt by 6.4% in the second quarter. California Public Employees Retirement System now owns 193,805 shares of the company’s stock valued at $519,000 after acquiring an additional 11,605 shares during the period. ProShare Advisors LLC bought a new stake in Mallinckrodt in the second quarter valued at about $32,000. Finally, Sontag Advisory LLC increased its stake in Mallinckrodt by 57.9% in the second quarter. Sontag Advisory LLC now owns 40,000 shares of the company’s stock valued at $107,000 after acquiring an additional 14,668 shares during the period. 61.67% of the stock is currently owned by institutional investors and hedge funds.
Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza.
Recommended Story: What is the Hang Seng index?
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.